ArticleCureus2025
Isolated Intracranial Recurrence of Burkitt Lymphoma Complicated by Dural Thickening: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Burkitt lymphoma (BL) usually involves extranodal regions such as the bone marrow and central nervous system (CNS), but dural involvement is rarely reported. We report a case of the intracranial recurrence of BL involving the CNS, leptomeninges, and dura mater. The patient was a 76-year-old woman who presented with systemic lymphadenopathies, bilateral pleural effusion, and ascites. Laboratory examination showed elevated white blood counts with circulating abnormal cells and thrombocytopenia. Bone marrow examination revealed the presence of abnormal medium-sized lymphocytes with cytoplasmic vacuoles, and IGH::MYC fusion gene was detected in these abnormal lymphocytes. Thus, the diagnosis of BL was made. No CNS lesions were identified at diagnosis. A complete metabolic response was achieved by rituximab combination chemotherapy with prophylactic intrathecal chemotherapy, but isolated intracranial recurrence of BL occurred. In intracranial recurrence, dural involvement was observed in addition to the leptomeninges. High-dose chemotherapy was not effective for relapsed BL, and she died because of disease progression. At autopsy, subdural hematoma (SDH) and dural thickening were pathologically found. This is a rare case of isolated intracranial BL recurrence with dural involvement and nontraumatic SDH as a complication, and we reviewed previous reports of secondary dural involvement in BL. Our case showed the important viewpoint that in the case of dural involvement, clinicians should be aware of the nontraumatic SDH as a complication, and whole-brain radiotherapy may be the optimal treatment for isolated intracranial BL recurrence with dural involvement after rituximab combination chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.